March 3, 2016 – The Institute for Clinical and Economic Review (ICER) has posted a draft scoping document that will inform a report assessing the comparative effectiveness and value of diabetes prevention programs.
The Centers for Disease Control and Prevention (CDC) estimates that 1.7 million adults are newly diagnosed with diabetes mellitus each year. Efforts to prevent diabetes through diet and lifestyle change have the potential to save the healthcare system substantial medical costs by reducing the number of people who will develop diabetes and its associated complications.
ICER’s report will include a systematic review of the published evidence, an analysis of the costs to implement diabetes prevention programs and their potential budgetary impact, and a summary of the policy landscape for diabetes prevention programs. The policy analysis will identify key programs and will examine the legal, regulatory, and financial landscape for diabetes prevention efforts.
The report will be the subject of the June 24, 2016 public meeting of the California Technology Assessment Forum (CTAF) where the CTAF Panel will vote on key questions raised in the report and a policy roundtable will discuss recommendations to apply the evidence to policy and practice.
Members of the public are encouraged to submit suggested refinements or additions to the scope via email to email@example.com. The scoping document will be open to public comment for a period of one week. Comments must be received by 5:00 PM PST on Thursday, March 10, 2016 and must adhere to guidelines described in the public comment guide.
Additional key dates for the draft reports, as well as further information about the June meeting, are included below:
|March 3||Draft scoping document posted|
|March 3 – March 10||Public comment on scoping document|
|April 1||Final scoping document posted|
|May 5||Initial draft report and voting questions posted|
|May 5- May 19||Public comment period for draft report and voting questions|
|June 6||Revised draft report and voting questions posted|
|June 24||Public meeting|
|On or about July 25||Final report posted|
CTAF Meeting Details
Date: June 24
Location: Los Angeles, CA
Additional detail will be posted to the CTAF website as they become available.
The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.
ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.